2018 - The Year of the BioTechs, page-626

The worm has turned. My prediction is that in 2018/19 CDY will be one of the best performers on the ASX. The planets are all aligned and I wouldn't be surprised if the business is cashflow positive within six months. Diversified biotech operating in a mega trend sphere of clinical science, anti ageing products first and best in class. Shareholders just need Cellmid to be recognised by others who currently have blinkers on. Build it and they will come! Have a good weekend all